Form D · Biotechnology
22nd Century Group, Inc.
Mocksville, NC · CIK 0001347858
Offering snapshot reported Oct 4, 2024 · SEC filing
- Reported sold
- $1.2M Offering amount: $1.2M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 27, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 4, 2024 | Initial | $1,200,000 | No comparison | 7 | SEC filing |
| Apr 19, 2024 | Initial | $4,200,000 | No comparison | 9 | SEC filing |
| Jul 29, 2022 | Initial | $35,000,009 | No comparison | 14 | SEC filing |
| May 27, 2022 | Amendment | $58,003,000 | $0vs May 25, 2022 | 64 | SEC filing |
| May 25, 2022 | Initial | $58,003,000 | No comparison | 64 | SEC filing |
| Sep 18, 2014 | Initial | $10,000,000 | No comparison | 1 | SEC filing |
| Feb 6, 2013 | Initial | $67,200 | No comparison | 1 | SEC filing |
| Nov 15, 2012 | Initial | $2,428,500 | No comparison | 20 | SEC filing |
| Aug 24, 2012 | Initial | $530,000 | No comparison | 4 | SEC filing |
| May 30, 2012 | Initial | $2,734,167 | No comparison | 19 | SEC filing |
| Dec 28, 2011 | Initial | $1,926,250 | No comparison | 24 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $70.5K
- Finders' fees
- $0
- Form D file number
- 021-525954
Also 309,211 warrants
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Dawson James Securities, Inc. | 130645 |
Source: Form D, filed Oct 4, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Andy Arno | Director |
| John T. Brodfuehrer | Executive |
| James W. Cornell | Director |
| Joseph Alexander Dunn | Director |
| Lawrence Firestone | Director, Executive |
| Richard Fitzgerald | Executive |
| Clifford B. Fleet | Director |
| John Franzino | Executive |
| Thomas L. James | Executive |
| Anthony Johnson | Director |
| Staffeldt P. Jonathan | Executive |
| Steven Katz | Director |
| Hugh Kinsman | Executive |
| Michael Koganov | Director |
| John Miller | Executive |
| James A Mish | Director |
| Michael R. Moynihan | Executive |
| Roger D. O'brien | Director |
| Daniel Otto | Executive |
| Joseph Nmn Pandolfino | Director, Executive |
| Steven Przybyla | Executive |
| C. Anthony Rider | Executive |
| Lucille S. Salhany | Director |
| Richard M. Sanders | Director |
| Henry Nmn Sicignano, Iii | Director, Executive |
| Nora B. Sullivan | Director |
| Michael Zercher | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
321 Farmington Road
Mocksville, NC, 27028
Mocksville, NC, 27028